RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement
RedHill Biopharma, a co-commercialization partner of Cumberland Pharmaceuticals for the drug Talicia, closed a private placement raising $6 million in upfront proceeds. The offering consisted of 8,571,429 ADSs priced at $0.70, with warrants that could generate an additional $13.4 million if exercised in full.
Key figures
- Deal Value Usd
- $6 million
- Offering Price
- 0.7
- Shares Offered
- 8571429
- Total potential proceeds
- $19.4 million
- Potential warrant proceeds
- $13.4 million
- Series a1 warrant exercise price
- $0.86
- Series a2 warrant exercise price
- $0.70
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.